排序方式： 共有733条查询结果，搜索用时 15 毫秒
51.
52.
Albert I Matti BSc BMBS Niladri Saha BSc MBChB FRCOphth FRANZCO 《Clinical & experimental optometry》2012,95(6):653-654
We describe the abuse of a topical ocular anaesthetic in a contact lens wearer who developed microbial keratitis. 相似文献
53.
54.
55.
56.
57.
Scalp Tumors Treated with Mohs Micrographic Surgery: Clinical Features and Surgical Outcome 总被引：3，自引：0，他引：3
IGAL LEIBOVITCH MD SHYAMALA C. HUILGOL FACD SHAWN RICHARDS FACD ROBERT PAVER FACD DINESH SELVA FRANZCO 《Dermatologic surgery》2006,32(11):1369-1374
BACKGROUND: There are only a small number of reports on the outcome of scalp tumors treated with Mohs micrographic surgery (MMS). OBJECTIVE: The objective was to present a large series of patients with scalp tumors treated with MMS in Australia between 1993 and 2002. METHODS: This prospective, multicenter study included all patients with scalp tumors who were monitored by the Skin and Cancer Foundation Australia. The variables analyzed were patient demographics, reason for referral, preoperative tumor size and postoperative defect size, recurrences before MMS, histologic subtypes, perineural invasion, and 5-year recurrence. RESULTS: The study included 316 patients (68% men) with a mean age of 65+/-15 years. The most common tumors were basal cell carcinoma (BCC), 57.9%; squamous cell carcinoma (SCC), 35.8%; Bowen's disease (BD), 4.1%; and atypical fibroxanthoma (AFX), 1.6%. Recurrent tumors comprised 37% of cases. The recurrence rate for 70 BCC patients who completed the 5-year follow-up was 5.7%, and for 31 SCC cases it was 3.2%. No cases of recurrence were noted in the patients with BD and AFX. CONCLUSION: BCC was the most common scalp tumor managed by MMS. The low 5-year recurrence rate emphasizes the importance of margin controlled excision of scalp tumors. 相似文献
58.
59.
60.
Hugh R Taylor AC FRANZCO Mitchell D Anjou MScOptom 《Clinical & experimental ophthalmology》2013,41(5):508-512
In 2001, one of the authors wrote in the Medical Journal of Australia about trachoma explaining that Australia is the only developed country in the world where blinding trachoma still exists. Ten years later, the same is still true, but there is some progress and the situation in Australia is starting to change. However, this progress has been somewhat glacial, especially compared with the rapid changes being made in other ‘undeveloped’ parts of the world. 相似文献